What does the March 04, 2026 IBRX analyst rating from Piper Sandler mean?

Piper Sandler’s **Overweight** on March 04, 2026 means the firm expects ImmunityBio to outperform peers. The note also raised the price target to **$12**, offering investors a valuation benchmark against current market pricing.

How should investors use the IBRX analyst rating and $12 price target?

Use the IBRX analyst rating and **$12** target as a reference when modeling scenarios and sizing positions. Combine the rating with trial milestones, cash runway, and broader analyst checks before changing allocation.

Does the IBRX analyst rating indicate a buy or sell signal?

An **Overweight** rating signals relative optimism versus the coverage universe, not a guaranteed buy. Investors should weigh company fundamentals, upcoming catalysts, and personal risk tolerance.

How reliable is the Meyka grade for IBRX in light of this analyst rating?

Meyka AI rates IBRX with a grade of **B+** based on benchmarks, sector performance, financial growth, key metrics, and analyst consensus. The grade is a guidance tool and not a substitute for individual due diligence.

Analyst Ratings

Piper Sandler Maintains Overweight on ImmunityBio (IBRX) March 2026

ByHuzaifa Zahoor March 5, 2026March 5, 2026

The latest IBRX analyst rating update shows Piper Sandler maintained an Overweight view on ImmunityBio, Inc. (IBRX) on March 04, 2026. Piper Sandler also raised its price target to $12, signaling continued conviction in the company’s clinical and commercial prospects. The note arrives as shares moved, with a reported -10.2% (-$1.02) price change since the communication. This IBRX analyst rating keeps the firm in the more favorable tier of coverage and gives investors a clear reference point for valuation and risk assessment.